載入...
Composite cognitive and functional measures for early stage Alzheimer's disease trials
INTRODUCTION: Composite scales have been advanced as primary outcomes in early stage Alzheimer's disease trials, and endorsed by the U.S. Food and Drug Administration (FDA) for pivotal trials. They are generally composed of several neurocognitive subscales and may include clinical and functiona...
Na minha lista:
| 發表在: | Alzheimers Dement (Amst) |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7233425/ https://ncbi.nlm.nih.gov/pubmed/32432155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dad2.12017 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|